FX.co ★ Why Hoth Therapeutics Is Rising In Pre-market?

Hoth Therapeutics (HOTH) has secured an exclusive patent license agreement with the U.S. Department of Veterans Affairs, granting the company unique rights to a patent portfolio collaboratively developed by the U.S. Department of Veterans Affairs and Emory University. This portfolio's technology is focused on Glial Cell Line-Derived Neurotrophic Factor, as well as obesity and associated diseases and conditions. With this agreement, Hoth Therapeutics gains sole rights to advance, market, and bring to market products and processes using these patents.

Furthermore, Hoth Therapeutics has taken steps to safeguard its intellectual property by drafting a Letter of Intent (LOI) to obtain additional provisional patent protection for its therapeutic product, HT-001.

On Thursday, shares of Hoth Therapeutics saw a 9% increase in pre-market trading.